JP2010520181A - 心血管疾患の予測および治療のためのオステオポンチン - Google Patents
心血管疾患の予測および治療のためのオステオポンチン Download PDFInfo
- Publication number
- JP2010520181A JP2010520181A JP2009551228A JP2009551228A JP2010520181A JP 2010520181 A JP2010520181 A JP 2010520181A JP 2009551228 A JP2009551228 A JP 2009551228A JP 2009551228 A JP2009551228 A JP 2009551228A JP 2010520181 A JP2010520181 A JP 2010520181A
- Authority
- JP
- Japan
- Prior art keywords
- osteopontin
- diabetes
- disease
- cardiovascular disease
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010081689 Osteopontin Proteins 0.000 title claims abstract description 167
- 102000004264 Osteopontin Human genes 0.000 title claims abstract description 166
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 44
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 34
- 210000000130 stem cell Anatomy 0.000 claims abstract description 24
- 230000003511 endothelial effect Effects 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 230000014509 gene expression Effects 0.000 claims description 50
- 210000004027 cell Anatomy 0.000 claims description 30
- 208000028867 ischemia Diseases 0.000 claims description 30
- 230000002792 vascular Effects 0.000 claims description 28
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 17
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 9
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000019553 vascular disease Diseases 0.000 claims description 8
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000007812 deficiency Effects 0.000 abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- 208000013600 Diabetic vascular disease Diseases 0.000 abstract description 2
- 201000009101 diabetic angiopathy Diseases 0.000 abstract description 2
- 239000003550 marker Substances 0.000 abstract description 2
- 230000037361 pathway Effects 0.000 abstract description 2
- 102100040557 Osteopontin Human genes 0.000 abstract 1
- 210000001956 EPC Anatomy 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 22
- 210000005239 tubule Anatomy 0.000 description 20
- 210000003141 lower extremity Anatomy 0.000 description 17
- 210000002889 endothelial cell Anatomy 0.000 description 15
- 230000001771 impaired effect Effects 0.000 description 13
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 12
- 230000033115 angiogenesis Effects 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 239000013615 primer Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000003753 real-time PCR Methods 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004413 cardiac myocyte Anatomy 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000000302 ischemic effect Effects 0.000 description 8
- 102000016359 Fibronectins Human genes 0.000 description 7
- 108010067306 Fibronectins Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000010208 microarray analysis Methods 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000012137 double-staining Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- ZAUYNCUCMJDAHW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;hydrogen peroxide;molecular iodine Chemical compound OO.II.C=CN1CCCC1=O ZAUYNCUCMJDAHW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VVABURGTPJVRMI-SHYZEUOFSA-N 3-bromo-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N(Br)C(=O)C=C1 VVABURGTPJVRMI-SHYZEUOFSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 241001479434 Agfa Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000012355 Integrin beta1 Human genes 0.000 description 1
- 108010022222 Integrin beta1 Proteins 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 238000010165 Scheffé test Methods 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241001325280 Tricardia watsonii Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015916 branching morphogenesis of a tube Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000001054 cardiac fibroblast Anatomy 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000003064 k means clustering Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000001292 preischemic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE20070136 | 2007-03-02 | ||
| IE20070901 | 2007-12-10 | ||
| PCT/EP2008/052578 WO2008107422A1 (en) | 2007-03-02 | 2008-03-03 | Osteopontin for the prediction and treatment of cardiovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010520181A true JP2010520181A (ja) | 2010-06-10 |
| JP2010520181A5 JP2010520181A5 (enExample) | 2012-04-19 |
Family
ID=39434086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009551228A Pending JP2010520181A (ja) | 2007-03-02 | 2008-03-03 | 心血管疾患の予測および治療のためのオステオポンチン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8323968B2 (enExample) |
| EP (1) | EP2114422A1 (enExample) |
| JP (1) | JP2010520181A (enExample) |
| AU (1) | AU2008223817A1 (enExample) |
| CA (1) | CA2679545A1 (enExample) |
| WO (1) | WO2008107422A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2596412A1 (en) | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
| US20110008328A1 (en) * | 2007-04-17 | 2011-01-13 | Pfizer Inc. | Method for controlling glucose uptake and insulin sensitivity |
| WO2009085270A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions |
| EP2252689A2 (en) * | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides for the treatment of surgical adhesions |
| EP2240583A2 (en) * | 2008-01-07 | 2010-10-20 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
| WO2011058182A1 (en) * | 2009-11-13 | 2011-05-19 | National University Of Ireland, Galway | Osteopontin-conditioned medium for the treatment of vascular diseases |
| JP6683686B2 (ja) | 2014-08-22 | 2020-04-22 | オークランド ユニサービシーズ リミティド | チャネル調節剤 |
| CN111201247A (zh) | 2017-04-28 | 2020-05-26 | 奥克兰联合服务有限公司 | 治疗方法和新颖构建体 |
| WO2018202870A1 (en) * | 2017-05-04 | 2018-11-08 | Follicum Ab | Peptides for treatment of diabetes |
| JP7553115B2 (ja) * | 2018-11-07 | 2024-09-18 | フォリクム エービー | 糖尿病治療のためのペプチド断片 |
| WO2021024265A1 (en) * | 2019-08-08 | 2021-02-11 | Ramot At Tel-Aviv University Ltd. | Methods of treating non-infectious inflammatory disorders |
| WO2021183786A2 (en) * | 2020-03-11 | 2021-09-16 | University Of Florida Research Foundation, Incorporated | Methods, devices, and compositions for lesion repair and prevention |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001503427A (ja) * | 1996-11-08 | 2001-03-13 | セント エリザベス メディカル センター オブ ボストン インク． | 血管新生を制御する方法 |
| JP2004509847A (ja) * | 2000-06-05 | 2004-04-02 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | ヒト骨髄由来内皮前駆細胞の同定、及び虚血性傷害後の心筋細胞の機能を改善するためのヒト骨髄由来内皮前駆細胞の使用 |
| WO2005085424A2 (en) * | 2004-03-09 | 2005-09-15 | Absorber Ab | Endothelial progenitor cells and methods of use thereof |
| WO2006042017A2 (en) * | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| WO2006060779A2 (en) * | 2004-12-03 | 2006-06-08 | Case Western Reserve University | Novel methods, compositions and devices for inducing neovascularization |
| JP2006217801A (ja) * | 2003-01-15 | 2006-08-24 | Kirin Brewery Co Ltd | ＴＧＦβ阻害活性を有する化合物の新規用途 |
| WO2007012764A2 (fr) * | 2005-07-27 | 2007-02-01 | Institut Des Vaisseaux Et Du Sang | Système marqueur cellulaire/ligand, où le marqueur est du type eph, matériau cellulaire comprenant ce système, procédé de préparation et utilisation proangiogénique |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9510498A (en) * | 1997-09-26 | 1999-04-12 | University Of Washington | Methods and compositions for diagnosing renal pathologies |
| US6414219B1 (en) | 1998-06-30 | 2002-07-02 | Rutgers, The State University Of New Jersey | Osteopontin knock-out mouse and methods of use thereof |
| US6551990B2 (en) * | 1998-12-07 | 2003-04-22 | University Of Washington | Methods of inhibiting ectopic calcification |
| AU2002357748A1 (en) * | 2001-11-21 | 2003-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Osteopontin-related compositions and methods |
| JP2004222836A (ja) * | 2003-01-21 | 2004-08-12 | Tissue Engineering Initiative Co Ltd | 培養真皮シートの製造方法および培養真皮シート |
| US20100150885A1 (en) * | 2005-06-01 | 2010-06-17 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| WO2007024649A2 (en) * | 2005-08-19 | 2007-03-01 | X-Cell Medical Incorporated | Methods of treating and preventing acute myocardial infarction |
-
2008
- 2008-03-03 AU AU2008223817A patent/AU2008223817A1/en not_active Abandoned
- 2008-03-03 US US12/528,610 patent/US8323968B2/en not_active Expired - Fee Related
- 2008-03-03 EP EP08717341A patent/EP2114422A1/en not_active Withdrawn
- 2008-03-03 JP JP2009551228A patent/JP2010520181A/ja active Pending
- 2008-03-03 CA CA002679545A patent/CA2679545A1/en not_active Abandoned
- 2008-03-03 WO PCT/EP2008/052578 patent/WO2008107422A1/en not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001503427A (ja) * | 1996-11-08 | 2001-03-13 | セント エリザベス メディカル センター オブ ボストン インク． | 血管新生を制御する方法 |
| JP2004509847A (ja) * | 2000-06-05 | 2004-04-02 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | ヒト骨髄由来内皮前駆細胞の同定、及び虚血性傷害後の心筋細胞の機能を改善するためのヒト骨髄由来内皮前駆細胞の使用 |
| JP2006217801A (ja) * | 2003-01-15 | 2006-08-24 | Kirin Brewery Co Ltd | ＴＧＦβ阻害活性を有する化合物の新規用途 |
| WO2005085424A2 (en) * | 2004-03-09 | 2005-09-15 | Absorber Ab | Endothelial progenitor cells and methods of use thereof |
| WO2006042017A2 (en) * | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| WO2006060779A2 (en) * | 2004-12-03 | 2006-06-08 | Case Western Reserve University | Novel methods, compositions and devices for inducing neovascularization |
| WO2007012764A2 (fr) * | 2005-07-27 | 2007-02-01 | Institut Des Vaisseaux Et Du Sang | Système marqueur cellulaire/ligand, où le marqueur est du type eph, matériau cellulaire comprenant ce système, procédé de préparation et utilisation proangiogénique |
Non-Patent Citations (4)
| Title |
|---|
| JPN5010006936; ＩＩ ＭＡＳＡＡＫＩ: ＣＩＲＣＵＬＡＴＩＯＮ Ｖ１１２ Ｎ１７ ＳＵＰＰＬ Ｓ, 200510, Ｐ．Ｕ２１９ * |
| JPN5010006937; ＴＡＫＡＧＩ Ｈ: ＪＡＰＡＮＥＳＥ ＪＯＵＲＮＡＬ ＯＦ ＯＰＨＴＨＡＬＭＯＬＯＧＹ Ｖ４６ Ｎ３, 2002, Ｐ２７０-２７８ * |
| JPN6013005455; ＡＳＯＵ，Ｙ． ｅｔ ａｌ: 'Ｏｓｔｅｏｐｏｎｔｉｎ ｆａｃｉｌｉｔａｔｅｓ ａｎｇｉｏｇｅｎｅｓｉｓ， ａｃｃｕｍｕｌａｔｉｏｎ ｏｆ ｏｓｔｅｏｃｌａｓｔｓ， ａｎｄ ｒｅｓｏｒｐｔｉｏｎ ｉｎ ｅｃｔｏｐｉｃ ｂｏｎｅ' Ｅｎｄｏｃｒｉｎｏｌｏｇｙ Ｖｏｌ．１４２， Ｎｏ．３, 2001, ｐ．１３２５-３２ * |
| JPN6013005459; ＨＡＭＡＤＡ，Ｙ． ｅｔ ａｌ: 'Ａｎｇｉｏｇｅｎｉｃ ａｃｔｉｖｉｔｙ ｏｆ ｏｓｔｅｏｐｏｎｔｉｎ-ｄｅｒｉｖｅｄ ｐｅｐｔｉｄｅ ＳＶＶＹＧＬＲ' Ｂｉｏｃｈｅｍ Ｂｉｏｐｈｙｓ Ｒｅｓ Ｃｏｍｍｕｎ Ｖｏｌ．３１０， Ｎｏ．１, 2003, ｐ．１５３-７ * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2679545A1 (en) | 2008-09-12 |
| AU2008223817A1 (en) | 2008-09-12 |
| WO2008107422A1 (en) | 2008-09-12 |
| EP2114422A1 (en) | 2009-11-11 |
| US8323968B2 (en) | 2012-12-04 |
| US20100150877A1 (en) | 2010-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520181A (ja) | 心血管疾患の予測および治療のためのオステオポンチン | |
| Ibrahim et al. | Augmenting canonical Wnt signalling in therapeutically inert cells converts them into therapeutically potent exosome factories | |
| Chu et al. | Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Wharton's jelly | |
| Liu et al. | Hypoxia pretreatment of bone marrow mesenchymal stem cells facilitates angiogenesis by improving the function of endothelial cells in diabetic rats with lower ischemia | |
| Gao et al. | Adipose‐derived stem cells accelerate neovascularization in ischaemic diabetic skin flap via expression of hypoxia‐inducible factor‐1α | |
| US20110305673A1 (en) | Compositions and methods for tissue repair | |
| Haddad et al. | Nox2-derived reactive oxygen species contribute to hypercholesterolemia-induced inhibition of neovascularization: effects on endothelial progenitor cells and mature endothelial cells | |
| Huang et al. | Hypoxia-induced therapeutic neovascularization in a mouse model of an ischemic limb using cell aggregates composed of HUVECs and cbMSCs | |
| Ii et al. | Synergistic effect of adipose-derived stem cell therapy and bone marrow progenitor recruitment in ischemic heart | |
| US20200297775A1 (en) | Enhanced direct cardiac reprogramming | |
| JP2024133372A (ja) | 心不全の治療方法 | |
| Kleiman et al. | Elevated IGF2 prevents leptin induction and terminal adipocyte differentiation in hemangioma stem cells | |
| Corvelyn et al. | Muscle microbiopsy to delineate stem cell involvement in young patients: a novel approach for children with cerebral palsy | |
| Yu et al. | Activation of liver X receptor enhances the proliferation and migration of endothelial progenitor cells and promotes vascular repair through PI3K/Akt/eNOS signaling pathway activation | |
| Sheng et al. | TWEAK promotes endothelial progenitor cell vasculogenesis to alleviate acute myocardial infarction via the Fn14‑NF‑κB signaling pathway | |
| Zhang et al. | Gadd45g, a novel antidepressant target, mediates metformin-induced neuronal differentiation of neural stem cells via DNA demethylation | |
| US20210137959A1 (en) | Agents and methods using thereof for the prevention and treatment of stem cell muscle disorders | |
| Pernomian et al. | Single-short partial reprogramming of the endothelial cells decreases blood pressure via attenuation of EndMT in hypertensive mice | |
| WO2007142651A1 (en) | Methods and compositions for the treatment of neuropathy | |
| Park et al. | Human cardiac stem cells rejuvenated by modulating autophagy with MHY-1685 enhance the therapeutic potential for cardiac repair | |
| TW201216973A (en) | Skin activation by means of pdgf-bb activity enhancement | |
| Du et al. | HIF‑1α overexpression improves the efficacy of human induced pluripotent stem cell‑derived cardiomyocytes for cardiac repair following myocardial infarction | |
| KR101723292B1 (ko) | Kai1 폴리펩타이드 또는 이를 코딩하는 유전자를 포함하는 혈관신생 억제용 조성물 및 이의 용도 | |
| Kim et al. | Combined growth factors enhanced angiogenic potential of cord blood-derived mononuclear cells transplanted to ischemic limbs | |
| Blei | Update June 2021 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110225 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130206 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130502 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130513 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130726 |